EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and safety of fenoldopam for the treatment of hypertensive crises in children with kidney disease: a retrospective study

Nicola Bertazza Partigiani, Serena Vigezzi, Davide Meneghesso, Matteo Tinnirello, Alessandra Rosalba Brazzale, Marco Daverio, Enrico Vidal

Pediatric Nephrology · 2025

DOI: 10.1007/s00467-024-06490-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Nephrology, 2025. Verfasst von Nicola Bertazza Partigiani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department for Women's and Children's Health, University of Padua, Padua, Italy. nicola.bertazzapartigiani@aopd.veneto.it. Hauptthemen laut MEDLINE: Fenoldopam, Antihypertensive Agents, Hypertension. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Padova.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hypertensive crises in children represent critical medical situations characterized by severe hypertension and potential organ damage. Fenoldopam, a dopaminergic medication, offers a viable therapeutic option for managing such clinical scenarios. We aimed to evaluate efficacy and safety of fenoldopam in the management of hypertensive urgencies and emergencies.

Methods

This retrospective analysis focused on pediatric patients affected by acute or chronic kidney disease, aged 1 month–18 years, admitted to the Pediatric Nephrology and the Pediatric Intensive Care Unit at University-Hospital of Padua, Italy, who presented with a hypertensive crisis treated with fenoldopam between March 2010 and December 2022.

Results

The study included 74 patients with median age 10 years (interquartile range [IQR] 4–15 years) who received 102 fenoldopam infusions. Seventy-two percent were already receiving antihypertensive treatment before admission. In all cases, fenoldopam was associated with a reduction of blood pressure (BP) after 8 h of treatment, but in 87% of patients reduction of the initial mean arterial pressure (MAP) was higher than 25% of calculated drop pressure. MAP normalized in 26% of cases after 24 h and in 35% after 48 h. Occurrence of hypotension was 7%, while hypokalemia was observed in 13% of cases. Patients who presented a MAP reduction not exceeding 25% of calculated drop pressure received a lower median fenoldopam dose (0.2 mcg/kg/min; IQR 0.1–0.2) compared with patients having a MAP reduction > 25% of calculated drop pressure (0.4 mcg/kg/min; IQR 0.2–0.6; p = 0.002).

Conclusions

Fenoldopam seems effective and safe for the treatment of hypertensive crises in children with kidney disease, at a starting dose of 0.2 mcg/kg/min. Strict BP monitoring is required to identify possible excessive drop pressure in the first hours of infusion. Graphical abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FenoldopamAntihypertensive AgentsHypertensionHumansRetrospective StudiesMaleChildFemaleChild, PreschoolAdolescentInfantTreatment OutcomeItalyBlood PressureRenal Insufficiency, ChronicHypertensive Crisis

Stichwörter der Autor:innen

Acute kidney injuryChronic kidney diseaseFenoldopamHypertension crisisPediatric

Substanzen

FenoldopamAntihypertensive Agents

Autor:innen und Institutionen

  • Department for Women's and Children's Health, University of Padua, Padua, Italy. nicola.bertazzapartigiani@aopd.veneto.it.
  • Department for Women's and Children's Health, University of Padua, Padua, Italy.
  • Pediatric Nephrology Unit, Department for Women's and Children's Health, University-Hospital of Padua, Padua, Italy.
  • Department of Statistical Sciences, University of Padua, Padua, Italy.
  • Pediatric Intensive Care Unit, Department of Women's and Children's Health, University Hospital of Padua, Padua, Italy.
  • Department of Medicine (DMED), University of Udine, Udine, Italy.

Förderung

  • Università degli Studi di Padova

Zitieren

APA

Bertazza Partigiani, N., Vigezzi, S., Meneghesso, D., Tinnirello, M., Brazzale, A. R., Daverio, M., & Vidal, E. (2025). Efficacy and safety of fenoldopam for the treatment of hypertensive crises in children with kidney disease: a retrospective study. Pediatric Nephrology. https://doi.org/10.1007/s00467-024-06490-7

Vancouver

Bertazza Partigiani N, Vigezzi S, Meneghesso D, Tinnirello M, Brazzale AR, Daverio M, et al. Efficacy and safety of fenoldopam for the treatment of hypertensive crises in children with kidney disease: a retrospective study. Pediatric Nephrology. 2025. doi:10.1007/s00467-024-06490-7

BibTeX
@article{BertazzaPartigiani2025,
  author = {Bertazza Partigiani, Nicola and Vigezzi, Serena and Meneghesso, Davide and Tinnirello, Matteo and Brazzale, Alessandra Rosalba and Daverio, Marco and Vidal, Enrico},
  title = {Efficacy and safety of fenoldopam for the treatment of hypertensive crises in children with kidney disease: a retrospective study},
  journal = {Pediatric Nephrology},
  year = {2025},
  doi = {10.1007/s00467-024-06490-7}
}
Kostenlos starten →